Elion Therapeutics
PrivateLast Round
Series B
Jun 17, 2024
Est. Valuation
$163M
Total Funding Raised
$81M
Company Overview
Elion Therapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series B round in June 2024.
Elion Therapeutics is a biotechnology company that develops next-generation polyene antifungal therapies to treat life-threatening invasive fungal infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elion Therapeutics Comparables
Compare Elion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| F2G | 83% | |
| Matinas BioPharma Holdings, Inc. | 81% | |
| Appili Therapeutics Inc. | 79% |
For institutional investors. Book with your work email.
Elion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 17, 2024 | ||||
| Seed | Jan 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Elion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Seed, Series A, Series B |
| AMR Action Fund | Series B |
| University of Illinois Foundation | Series B |
| Illinois Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Phase 2 study started for Turletricin (EL219) for invasive mould infections.
- Jun 17, 2024
$81M round led by Deerfield Management
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 21, 2026
Elion Therapeutics Inc. and its collaborators are set to present new turletricin clinical data at Infectious Disease Week (IDWeek) 2026, taking place Oct 21–24 in District of Columbia.
For institutional investors. Book with your work email.
Elion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Elion Therapeutics's valuation, stock price, and market status.
Is Elion Therapeutics a public or private company?
Elion Therapeutics is a private company.
What is the current stock price of Elion Therapeutics?
Elion Therapeutics is a private company, so its shares have no public market price. Caplight tracks Elion Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Elion Therapeutics worth (valuation)?
Elion Therapeutics's valuation is estimated at $163.0M based on funding round data.
Can I buy Elion Therapeutics stock?
Elion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Elion Therapeutics's last funding round?
Elion Therapeutics's most recent funding round was Series B on June 17, 2024.
Who are the main investors in Elion Therapeutics?
Key investors in Elion Therapeutics include Deerfield Management.
Will Elion Therapeutics IPO soon?
No public IPO plans have been announced for Elion Therapeutics.
How can I track Elion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Elion Therapeutics's shares on secondary markets.